Nourished

ApplicationBirmingham, United KingdomFounded 2019· One of 414 Application companies tracked by AMPulse

A personalized nutrition platform that utilizes proprietary 3D printing technology to create bespoke, 7-in-1 nutrient gummy 'stacks' tailored to an individual's specific health goals and lifestyle.

CEO / Founder: Melissa Snover
Team Size: 51-200
Stage: Active
Total Funding: $25.7M
Latest Round: Series B
Key Investors: Suntory Holdings, ADM Ventures, Cibus Fund, Henkel X, Future Planet Capital, Borski Fund, West Midlands Co-Investment Fund

Technology & Products

Key Products

["Personalized 7-in-1 Gummy Stacks (Core D2C offering)","SkinStacks (Co-branded with Neutrogena for skin health)","NutriStacks (Co-branded with Colgate for oral health)","UPSA x Nourished (Pharmacy-exclusive range in Europe)","Collagen+ and Menopause Support specialized ranges","Scripted (Personalized medicine arm for curative health)"]

Technological Advantage

Combines a proprietary AI-driven lifestyle algorithm with patented multi-material 3D printing and a unique vegan encapsulation formula that ensures ingredient integrity and optimal nutrient delivery.

Differentiation

Value Proposition

Replaces multiple supplement pills with a single, freshly 3D-printed gummy containing seven active ingredients, offering higher absorption rates and over 60 billion possible personalization permutations.

How They Differentiate

Proprietary 3D printing technology that combines seven different active ingredients into a single, personalized gummy 'stack,' eliminating the need for multiple separate pills and offering higher nutrient bioavailability.

Market & Competition

Target Customers

Health-conscious consumers, individuals with specific wellness needs (e.g., skin health, menopause, athletic performance), and retail pharmacy shoppers.

Industry Verticals

["HealthTech","FoodTech","Personalized Nutrition","Wellness & Beauty","Pharmaceuticals"]

Competitors

Care/of; Persona Nutrition; Baze; Ritual

Growth & Milestones

Growth Metrics

Estimated ARR of $10M - $20M; expanded retail footprint to over 10,000 pharmacies in Europe via UPSA partnership.

Major Milestones

["Raised record-breaking £2M seed round for a UK female founder in 2019","Launched 'SkinStacks' in collaboration with Neutrogena at CES 2023","Secured strategic partnership with Suntory for expansion into the Japanese market in 2024","Awarded King’s Award for Enterprise in Innovation 2024","Secured £9M growth funding in late 2024 to scale global manufacturing"]

Notable Customers

Neutrogena (Johnson & Johnson); Colgate-Palmolive; UPSA (French Pharmaceutical); Suntory

https://get-nourished.com

Why this company matters

Nourished occupies a unique position at the intersection of additive manufacturing and personalized nutrition, replacing the conventional regimen of multiple supplement pills with a single, freshly 3D-printed gummy. The company's proprietary platform combines an AI-driven lifestyle questionnaire with polymer material jetting (MJT) to produce bespoke 'stacks' that layer up to seven active ingredients in one vegan gummy. This approach addresses a common formulation challenge: incompatible ingredients that cannot coexist in a traditional pill or gummy can be deposited in separate layers, preserving their integrity and bioavailability.

The core product is a direct-to-consumer subscription of personalized 7-in-1 gummy stacks, but Nourished has extended its technology into co-branded and retail channels. SkinStacks, developed with Neutrogena (Johnson & Johnson), targets skin health; NutriStacks with Colgate-Palmolive focuses on oral health; and a pharmacy-exclusive range with UPSA reaches over 10,000 European pharmacies. The company also offers specialized ranges for collagen, menopause support, and a personalized medicine arm called Scripted. These partnerships demonstrate the platform's adaptability across wellness, beauty, and pharmaceutical verticals.

Nourished has raised approximately $25.7 million from investors including Suntory Holdings, ADM Ventures, and Henkel X. Its estimated ARR falls between $10 million and $20 million, and it was awarded the King's Award for Enterprise in Innovation in 2024. The company holds 29 approved patents covering its 3D printing manufacturing techniques and ingredient encapsulation methods. A key strategic question is whether the premium-priced D2C model can scale profitably as larger competitors like Care/of and Ritual also pursue personalization, and whether the pharmacy channel will drive sufficient volume to justify the capital-intensive manufacturing footprint.